Osimertinib (Tagrisso®) is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitising and EGFR T790M resistance mutations.1 In New Zealand, osimertinib is indicated for: adjuvant treatment after tumour resection in patients with EGFR-positive non-small cell lung cancer (NSCLC); firstline treatment of locally advanced/metastatic EGFR-mutated NSCLC; and treatment of locally advanced/metastatic EGFR T790M mutation-positive NSCLC.1 This review focusses on the pharmacological characteristics of osimertinib and data from key phase 3 NSCLC clinical trials.
Please login below to download this issue (PDF)